Clinical Trial Update: Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes [Phase 2]

View source ↗

Summary

This Phase 2 trial compared low-dose and standard-dose ticagrelor with clopidogrel to inhibit platelet reactivity in patients with acute coronary syndrome; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• BRILINTA (ticagrelor)
• Plavix (clopidogrel)

Snippet

Sponsor: Seung-Jung Park | Conditions: Acute Coronary Syndrome | Phase 2 | Status: COMPLETED